AIM
PGNX

Advantage Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Advantage Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed -$1K – 1111
2017
Q3 		$1K Hold
100
– – ﹤0.01% 1013
2017
Q2 		$1K Hold
100
– – ﹤0.01% 1061
2017
Q1 		$1K Hold
100
– – ﹤0.01% 960
2016
Q4 		$1K Buy
+100
New +$739 ﹤0.01% 939
2015
Q4 		– Sell
-1,500
Closed -$9K – 912
2015
Q3 		$9K Hold
1,500
– – 0.01% 568
2015
Q2 		$11K Hold
1,500
– – 0.01% 586
2015
Q1 		$9K Hold
1,500
– – 0.01% 613
2014
Q4 		$11K Buy
+1,500
New +$8.97K 0.01% 517

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Advantage Investment Management's PGNX Position: Q4 2017 in Review

Advantage Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 100 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in PGNX in Q4 2014 and held it in 8 quarters. The position peaked at $11K in Q2 2015. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Advantage Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Advantage Investment Management sold 100 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $1K.
  • Advantage Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 8 quarters.
  • Advantage Investment Management's Progenics Pharmaceuticals Inc position peaked at $11K in Q2 2015.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Advantage Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.